PHASE I/II TRIAL OF CPT-11 AND TEMOZOLOMIDE IN RECURRENT MALIGNANT GLIOMA

CPT-11 和替莫唑胺治疗复发性恶性胶质瘤的 I/II 期试验

• 批准号: 7375488
• 负责人: MINESH P. MEHTA
• 金额: $ 0.09万
• 依托单位: UNIVERSITY OF WISCONSIN-MADISON
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-12-01 至 2006-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7375488
• 关键词: PHASE; II; TRIAL; CPT; 11

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This study is closed to new enrollment. (Clinical trial summary from the National Cancer Institute's PDQ database) Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. This is a Phase I/II trial to study the effectiveness of temozolomide plus irinotecan in treating patients who have recurrent malignant glioma. Patients will receive temozolomide by mouth once a day on Days 1-5 and an infusion of irinotecan on Days 1 and 14. Treatment may be repeated every 4 weeks for up to 1 year. Patients will receive follow-up evaluations every 2 months for 1 year, every 3 months for 1 year, every 4 months for 1 year, and every 4-6 months thereafter.

本子项目是利用由NIH/NCRR资助的中心赠款提供的资源的众多研究子项目之一。子项目和研究者（PI）可能已经从另一个NIH来源获得了主要资金，因此可以在其他CRISP条目中表示。列出的机构是中心的，不一定是研究者的机构。本研究不接受新入组。（临床试验摘要来自美国国家癌症研究所的PDQ数据库）化疗中使用的药物使用不同的方法来阻止肿瘤细胞分裂，从而使它们停止生长或死亡。联合使用一种以上的药物可以杀死更多的肿瘤细胞。这是一项I/II期试验，旨在研究替莫唑胺加伊立替康治疗复发性恶性胶质瘤患者的有效性。患者将在第1-5天每天口服一次替莫唑胺，在第1天和第14天输注伊立替康。治疗可每4周重复1年。随访评估1年每2个月一次，1年每3个月一次，1年每4个月一次，此后每4-6个月一次。